Literature DB >> 3014879

Nitrous oxide, an opioid addictive agent. Review of the evidence.

M A Gillman.   

Abstract

Pharmacologic evidence that nitrous oxide is addictive through direct interaction with the endogenous opioid system includes the possibility that it is a partial agonist and acts at the mu, kappa, and sigma opioid receptors. The medical and psychiatric complications of its abuse are discussed with special reference to the 32 cases of myeloneuropathy so far reported; other dangers are also mentioned. Notwithstanding the extremely low incidence of reported cases of nitrous oxide addiction compared with all other addictive substances, greater controls should be placed on its commercial availability to at least maintain its low level of abuse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014879     DOI: 10.1016/0002-9343(86)90189-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Nitrous Oxide Toxicity: Case Files of the Carolinas Medical Center Medical Toxicology Fellowship.

Authors:  Kartik Shah; Christine Murphy
Journal:  J Med Toxicol       Date:  2019-08-06

2.  Analgesic nitrous oxide for alcohol withdrawal: a critical appraisal after 10 years' use.

Authors:  M A Gillman; F J Lichtigfeld
Journal:  Postgrad Med J       Date:  1990-07       Impact factor: 2.401

3.  Nitrous oxide and infertility.

Authors:  G Kugel; C Letelier; M A Zive; J C King
Journal:  Anesth Prog       Date:  1990-07

4.  PHEDRE trial protocol - observational study of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population.

Authors:  Marie Gérardin; Marie-Laure Couec; Marie Grall-Bronnec; Fanny Feuillet; Laura Wainstein; Morgane Rousselet; Marie-Lyne Pinot; Fanny Perrouin; Olivier Bonnot; Marie-Hélène Drouineau; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  BMC Psychiatry       Date:  2015-11-14       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.